Linatil Comp Mite

Enalapril maleate, the active ingredient in Linatil Comp Mite, is an ACE inhibitor presented as a combination tablet for oral use. It works together with hydrochlorothiazide to treat hypertension in adult patients requiring dual therapy.

GNH USA supplies Linatil Comp Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics across multiple regions, the product meets EU pharmacopoeial standards and is manufactured under strict Good Manufacturing Practices certified.

Linatil Comp Mite, a combination antihypertensive tablet, acts on the renin‑angiotensin system and renal sodium handling to lower blood pressure.

Hypertension: reduces systolic and diastolic pressure in patients with essential hypertension. Edema associated with heart failure: decreases fluid overload and improves symptom control in congestive heart failure. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes when combined with standard care.

Linatil Comp Mite may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Cough - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe dehydration or electrolyte imbalance - Hyperkalemia - Acute kidney injury - Significant hypotension - Blood dyscrasias such as agranulocytosis

Before prescribing Linatil Comp Mite, clinicians should consider several safety precautions.

Monitor blood pressure: ensure adequate control and avoid excessive hypotension. Assess renal function: check serum creatinine and eGFR prior to initiation and periodically. Check electrolytes: monitor serum potassium and sodium levels during therapy. Avoid in patients with known angioedema: contraindicated due to risk of recurrence. Use caution in pregnancy: limited data, risk‑benefit assessment required. Store below 25°C: keep in the original container, protect from moisture and light.

Linatil Comp Mite can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or potassium supplements: may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): can reduce antihypertensive effect and impair renal function. - Lithium: ACE inhibition can raise lithium levels, risking toxicity. - Dual therapy with other ACE inhibitors or ARBs: excessive renin‑angiotensin blockade.

Moderate Interactions (Monitor Closely): - Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance blood‑pressure lowering, requiring dose adjustments. - Loop diuretics: additive diuretic effect may lead to volume depletion. - Corticosteroids: can increase sodium retention, counteracting diuretic effect. - Antidiabetic agents: blood‑glucose may improve, requiring monitoring of hypoglycemia. - Antimicrobials such as trimethoprim‑sulfamethoxazole: may increase risk of hyperkalemia.